Alan Ashworth

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. pmc Molecular response to aromatase inhibitor treatment in primary breast cancer
    Alan Mackay
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London, SW3 6JB, UK
    Breast Cancer Res 9:R37. 2007
  2. ncbi request reprint Dissecting resistance to endocrine therapy in breast cancer
    Christopher J Lord
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
    Cell Cycle 7:1895-8. 2008
  3. pmc NLK is a novel therapeutic target for PTEN deficient tumour cells
    Ana M Mendes-Pereira
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
    PLoS ONE 7:e47249. 2012
  4. ncbi request reprint Interview: An interview with Pharmacogenomics for the breast cancer special focus issue
    Alan Ashworth
    The Breakthrough Breast Cancer Research Centre, 237 Fulham Road, London, UK
    Pharmacogenomics 13:651-4. 2012
  5. pmc DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1
    Sarah A Martin
    Cancer Research UK Gene Function and Regulation Group, The Institute of Cancer Research, London SW3 6JB, UK
    Cancer Cell 17:235-48. 2010
  6. pmc Pregnancy in the mature adult mouse does not alter the proportion of mammary epithelial stem/progenitor cells
    Kara L Britt
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    Breast Cancer Res 11:R20. 2009
  7. pmc CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells
    Katherine E Sleeman
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    Breast Cancer Res 8:R7. 2006
  8. pmc Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines
    Kevin C H Ha
    Department of Human Genetics, McGill University, Montreal, Quebec, H3A 1B1, Canada
    BMC Med Genomics 4:75. 2011
  9. pmc An RNA interference screen for identifying downstream effectors of the p53 and pRB tumour suppressor pathways involved in senescence
    Emilie Rovillain
    Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK
    BMC Genomics 12:355. 2011
  10. pmc Neuregulin3 alters cell fate in the epidermis and mammary gland
    Heena Panchal
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research 237 Fulham Road, London SW3 6JB, UK
    BMC Dev Biol 7:105. 2007

Detail Information

Publications130 found, 100 shown here

  1. pmc Molecular response to aromatase inhibitor treatment in primary breast cancer
    Alan Mackay
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London, SW3 6JB, UK
    Breast Cancer Res 9:R37. 2007
    ..Little is known of the molecular effects of these agents on human breast carcinomas in vivo...
  2. ncbi request reprint Dissecting resistance to endocrine therapy in breast cancer
    Christopher J Lord
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
    Cell Cycle 7:1895-8. 2008
    ..The results of a high-throughput RNA interference screen identifying novel determinants of tamoxifen resistance support this conjecture and demonstrate that such approaches can identify clinically relevant genes, such as CDK10...
  3. pmc NLK is a novel therapeutic target for PTEN deficient tumour cells
    Ana M Mendes-Pereira
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
    PLoS ONE 7:e47249. 2012
    ..Taken together, these data provide new insight into the potential of targeting of NLK to treat a range of tumourigenic conditions characterised by PTEN deficiency...
  4. ncbi request reprint Interview: An interview with Pharmacogenomics for the breast cancer special focus issue
    Alan Ashworth
    The Breakthrough Breast Cancer Research Centre, 237 Fulham Road, London, UK
    Pharmacogenomics 13:651-4. 2012
    b>Alan Ashworth speaks to Sarah Miller, Assistant Commissioning Editor Alan Ashworth joined the Institute of Cancer Research (ICR; London, UK) in 1986 as a postdoctoral scientist in the Section of Cell and Molecular Biology...
  5. pmc DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1
    Sarah A Martin
    Cancer Research UK Gene Function and Regulation Group, The Institute of Cancer Research, London SW3 6JB, UK
    Cancer Cell 17:235-48. 2010
    ..These data suggest targeted, mechanism-based therapeutic approaches...
  6. pmc Pregnancy in the mature adult mouse does not alter the proportion of mammary epithelial stem/progenitor cells
    Kara L Britt
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    Breast Cancer Res 11:R20. 2009
    ..However, the effects on stem/progenitor cell numbers in the mammary epithelium of a pregnancy in older animals have not yet been tested...
  7. pmc CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells
    Katherine E Sleeman
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    Breast Cancer Res 8:R7. 2006
    ..To date, this has been hampered by the lack of suitable markers to separate out the two epithelial layers, and to remove contaminating non-epithelial cells...
  8. pmc Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines
    Kevin C H Ha
    Department of Human Genetics, McGill University, Montreal, Quebec, H3A 1B1, Canada
    BMC Med Genomics 4:75. 2011
    ..We sought to identify putative gene fusions in the transcriptomes of these cancers using high-throughput RNA sequencing (RNA-Seq)...
  9. pmc An RNA interference screen for identifying downstream effectors of the p53 and pRB tumour suppressor pathways involved in senescence
    Emilie Rovillain
    Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK
    BMC Genomics 12:355. 2011
    ....
  10. pmc Neuregulin3 alters cell fate in the epidermis and mammary gland
    Heena Panchal
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research 237 Fulham Road, London SW3 6JB, UK
    BMC Dev Biol 7:105. 2007
    ....
  11. ncbi request reprint Oh what a tangled web it weaves: BRCA1 and DNA decatenation
    Alan Ashworth
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Fulham Road, London SW3 6JB, United Kingdom
    Cancer Cell 8:95-7. 2005
    ..2005) in Nature Structural and Molecular Biology. Ineffective DNA decatenation may lead to chromosome breakage and inappropriate repair, adding to the roll call of defects in BRCA1 mutant cells...
  12. doi request reprint Genetic interactions in cancer progression and treatment
    Alan Ashworth
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    Cell 145:30-8. 2011
    ..Here, we discuss the implications of these findings for cancer progression and heterogeneity and for the development of new therapeutic approaches...
  13. pmc Using functional genetics to understand breast cancer biology
    Alan Ashworth
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, SW3 6JB, United Kingdom
    Cold Spring Harb Perspect Biol 2:a003327. 2010
    ....
  14. ncbi request reprint Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007
    Alan Ashworth
    Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Gynecol Oncol 108:652-7. 2008
    ..As ovarian cancer becomes a chronic disease, greater emphasis will be placed on the challenges facing survivors...
  15. doi request reprint A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
    Alan Ashworth
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
    J Clin Oncol 26:3785-90. 2008
    ..This provides the basis for a novel synthetic lethal approach to cancer therapy...
  16. doi request reprint Drug resistance caused by reversion mutation
    Alan Ashworth
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London, United Kingdom
    Cancer Res 68:10021-3. 2008
    ..Furthermore, a similar mechanism seems to be associated with carboplatin resistance in some BRCA2 mutation carriers with ovarian cancer...
  17. doi request reprint Functional characterization of EMSY gene amplification in human cancers
    Paul M Wilkerson
    Molecular Pathology Team, Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 225:29-42. 2011
    ..Taken together, this suggests that EMSY is unlikely to be a driver of the 11q13-q14 amplicon and does not have a dominant role in modulating the response to agents targeting cells with defective homologous recombination...
  18. pmc Integrated functional, gene expression and genomic analysis for the identification of cancer targets
    Elizabeth Iorns
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
    PLoS ONE 4:e5120. 2009
    ..In conclusion, this strategy represents a novel and effective strategy for the identification of functionally important therapeutic targets in cancer...
  19. pmc A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
    Nicholas C Turner
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    EMBO J 27:1368-77. 2008
    ..These results highlight the potential of synthetic lethal siRNA screens with chemical inhibitors to define new determinants of sensitivity and potential therapeutic targets...
  20. doi request reprint DNA amplifications in breast cancer: genotypic-phenotypic correlations
    Kai Keen Shiu
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London SW36JB, UK
    Future Oncol 6:967-84. 2010
    ....
  21. ncbi request reprint FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas
    Jorge Sergio Reis-Filho
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 12:6652-62. 2006
    ..However, little is known about the putative therapeutic targets for these tumors. The aim of this study was to characterize CLCs at the molecular genetic level and identify putative therapeutic targets...
  22. pmc FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer
    Nicholas Turner
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Cancer Res 70:2085-94. 2010
    ..Our data suggest that amplification and overexpression of FGFR1 may be a major contributor to poor prognosis in luminal-type breast cancers, driving anchorage-independent proliferation and endocrine therapy resistance...
  23. doi request reprint Resistance to therapy caused by intragenic deletion in BRCA2
    Stacey L Edwards
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    Nature 451:1111-5. 2008
    ..6174delT mutation carriers. These observations have implications for understanding drug resistance in BRCA mutation carriers as well as in defining functionally important domains within BRCA2...
  24. doi request reprint Conditional deletion of the Lkb1 gene in the mouse mammary gland induces tumour formation
    Afshan McCarthy
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    J Pathol 219:306-16. 2009
    ..This mouse model of Lkb1 deficiency provides a potentially useful tool to investigate the role of Lkb1 in tumourigenesis and to guide the development of therapeutic approaches...
  25. doi request reprint PPM1D is a potential therapeutic target in ovarian clear cell carcinomas
    David S P Tan
    Department of Histopathology and Gynecologic Oncology, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Royal Marsden Hospital, London, United Kingdom
    Clin Cancer Res 15:2269-80. 2009
    ..To identify therapeutic targets in ovarian clear cell carcinomas, a chemoresistant and aggressive type of ovarian cancer...
  26. doi request reprint Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer
    Elizabeth Iorns
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    Cancer Cell 13:91-104. 2008
    ..The association of low levels of CDK10 with methylation of the CDK10 promoter suggests a mechanism by which CDK10 expression is reduced in tumors...
  27. ncbi request reprint Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility
    Nichola Johnson
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK
    Hum Mol Genet 16:1051-7. 2007
    ..A risk score incorporating a suitably weighted sum of all potentially functional variants in these and a few other candidate genes may provide clinically useful identification of women at high genetic risk...
  28. doi request reprint Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type
    Magali Lacroix-Triki
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 222:282-98. 2010
    ..Both components of mixed mucinous tumours are remarkably similar at the molecular level to pure mucinous cancers, suggesting that mixed mucinous carcinomas may be best classified as variants of mucinous cancers rather than of IDC-NSTs...
  29. doi request reprint Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines
    Edurne Arriola
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Lab Invest 88:491-503. 2008
    ..The 17q12 amplicon is complex and harbours multiple genes that may be associated with breast cancer development and progression, and potentially exploitable as therapeutic targets...
  30. doi request reprint CYP3A variation, premenopausal estrone levels, and breast cancer risk
    Nichola Johnson
    The Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, Institute of Cancer Research, London, UK
    J Natl Cancer Inst 104:657-69. 2012
    ..Our aim was to identify common variants in genes involved in sex steroid synthesis or metabolism that are associated with hormone levels and the risk of breast cancer in premenopausal women...
  31. pmc Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations
    Konstantin J Dedes
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    Cell Cycle 10:1192-9. 2011
    ..Here we discuss the evidence that the clinical use of PARP inhibition may be broader than targeting of cancers in BRCA1/2 germ-line mutation carriers...
  32. doi request reprint Genome-wide transcriptomic profiling of microdissected human breast tissue reveals differential expression of KIT (c-Kit, CD117) and oestrogen receptor-alpha (ERalpha) in response to therapeutic radiation
    Charlotte B Westbury
    Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 219:131-40. 2009
    ..The findings are relevant to both fibrosis and atrophy occurring after radiotherapy for early breast cancer...
  33. doi request reprint Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas
    Felipe C Geyer
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 220:562-73. 2010
    ..This proof-of-principle study provides direct evidence of intra-tumour genetic heterogeneity in breast cancers, and shows that in some cases morphological diversity may be underpinned by distinct genetic aberrations...
  34. ncbi request reprint Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis
    Kay Savage
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 13:90-101. 2007
    ....
  35. pmc Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity
    Ilirjana Bajrami
    Authors Affiliations The CRUK Gene Function Laboratory, Functional Genomics Laboratory, Breakthrough Breast Cancer Research Centre, and Tumour Profiling Unit, The Institute of Cancer Research, London, United Kingdom
    Cancer Res 74:287-97. 2014
    ....
  36. pmc APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer
    Rachel Brough
    Cancer Research UK Gene Function and Regulation Group, London, UK
    EMBO J 31:1160-76. 2012
    ....
  37. pmc Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancers
    Matthew J Smalley
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    Breast Cancer Res 9:R85. 2007
    ..We now investigate the relationship between cells expressing these markers and use gene expression microarray analysis to identify genes differentially expressed in the cell populations...
  38. pmc Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast
    Rachael Natrajan
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    J Pathol 232:553-65. 2014
    ..Although seemingly private genetic events, some of the fusion transcripts found in MPCs may play a role in maintenance of a malignant phenotype and potentially offer therapeutic opportunities...
  39. doi request reprint Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
    Louise J Barber
    Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 229:422-9. 2013
    ..These secondary mutations restored full-length BRCA2 protein, and most likely cause olaparib resistance by re-establishing BRCA2 function in the tumour cells...
  40. doi request reprint Synthetic lethal approaches to breast cancer therapy
    Farah L Rehman
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    Nat Rev Clin Oncol 7:718-24. 2010
    ..We discuss the current clinical developments in implementing synthetic lethality therapies, and highlight new ways in which this approach could be used to target specific subsets of breast cancer...
  41. doi request reprint BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells
    Gemma Molyneux
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK
    Cell Stem Cell 7:403-17. 2010
    ..They also demonstrate that when target cells for transformation have the potential for phenotypic plasticity, tumor phenotypes may not directly reflect histogenesis. This has important implications for cancer prevention strategies...
  42. doi request reprint CRK7 modifies the MAPK pathway and influences the response to endocrine therapy
    Elizabeth Iorns
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    Carcinogenesis 30:1696-701. 2009
    ..This study identifies a novel role for CRK7 in MAPK regulation and resistance to estrogen signaling inhibitors...
  43. doi request reprint Association of genetic variants at 8q24 with breast cancer risk
    Olivia Fletcher
    Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Cancer Epidemiol Biomarkers Prev 17:702-5. 2008
    ..25-fold increased risk of prostate cancer, with no effect for the two other variants, indicates that the effects of the risk alleles clustered at 8q24 are cancer site specific...
  44. doi request reprint Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components
    Caterina Marchio
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 218:301-15. 2009
    ....
  45. doi request reprint Tiling path genomic profiling of grade 3 invasive ductal breast cancers
    Rachael Natrajan
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Clin Cancer Res 15:2711-22. 2009
    ....
  46. doi request reprint A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines
    Alan Mackay
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London, SW3 6JB, UK
    Breast Cancer Res Treat 118:481-98. 2009
    ..e., gains of 1q, 8q and 20q), basal-like and luminal cell lines are characterised by distinct genomic aberrations...
  47. pmc A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers
    Rachael Natrajan
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK
    J Pathol 227:29-41. 2012
    ....
  48. doi request reprint PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study
    Maryou B Lambros
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Mod Pathol 23:1334-45. 2010
    ..Co-amplification of PPM1D and HER2/TOP2A and CCND1 are not random events and may suggest the presence of a 'firestorm' genetic profile...
  49. pmc Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls
    Olivia Fletcher
    British Breast Cancer Study, The Breakthrough Breast Cancer Research Centre, London, United Kingdom
    Cancer Epidemiol Biomarkers Prev 19:2143-51. 2010
    ..Truncating mutations in ATM have been shown to increase the risk of breast cancer but the effect of missense variants remains contentious...
  50. doi request reprint Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?
    Rachael Natrajan
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, UK
    Genes Chromosomes Cancer 48:351-65. 2009
    ..Given that GI breast cancers harbor a luminal phenotype, our results suggest that if progression from GI to GIII breast cancer does happen, it may preferentially occur in breast cancers of luminal phenotype...
  51. ncbi request reprint Hallmarks of 'BRCAness' in sporadic cancers
    Nicholas Turner
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    Nat Rev Cancer 4:814-9. 2004
    ..These common properties might have important implications for the clinical management of these cancers...
  52. pmc Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
    Ana M Mendes-Pereira
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    EMBO Mol Med 1:315-22. 2009
    ..The data we present here now suggests that the clinical assessment of PARP inhibitors should be extended beyond those with BRCA mutations to a larger group of patients with PTEN mutant tumours...
  53. pmc Genome-wide association studies identify four ER negative-specific breast cancer risk loci
    Montserrat Garcia-Closas
    1 Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, UK 2 Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK 3
    Nat Genet 45:392-8, 398e1-2. 2013
    ..0 × 10(-8)), were associated with ER-negative but not ER-positive breast cancer (P > 0.05). These findings provide further evidence for distinct etiological pathways associated with invasive ER-positive and ER-negative breast cancers...
  54. pmc Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data
    Anita Grigoriadis
    Ludwig Institute for Cancer Research University College London Breast Cancer Laboratory, 91 Riding House Street, London, W1W 7BS, UK
    Breast Cancer Res 8:R56. 2006
    ....
  55. pmc Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk
    Nick Orr
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    Nat Genet 44:1182-4. 2012
    ..A SNP in RAD51B at 14q24.1 was significantly associated with male breast cancer risk (P = 3.02 × 10(-13); odds ratio (OR) = 1.57). We also refine association at 16q12.1 to a SNP within TOX3 (P = 3.87 × 10(-15); OR = 1.50)...
  56. pmc Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer
    Elise Ruark
    Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton SM2 5NG, UK
    Nature 493:406-10. 2013
    ..More generally, these data provide new insights into the role of rare and of mosaic genetic variants in common conditions, and the use of sequencing in their identification...
  57. pmc Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen
    Ana M Mendes-Pereira
    Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, Institute of Cancer Research, London SW3 6JB, United Kingdom
    Proc Natl Acad Sci U S A 109:2730-5. 2012
    ..Multiple individual genes, including NF1, a regulator of RAS signaling, also correlate with clinical outcome after tamoxifen treatment...
  58. pmc Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement
    Alan Mackay
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Rd, London SW3 6JB, UK
    J Natl Cancer Inst 103:662-73. 2011
    ..The aim of this study was to determine the objectivity and interobserver reproducibility of the assignment of molecular subtype classes by hierarchical cluster analysis...
  59. doi request reprint A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity
    Christopher J Lord
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    DNA Repair (Amst) 7:2010-9. 2008
    ..Furthermore, the identification of these novel determinants may eventually guide the optimal use of PARP inhibitors in the clinic...
  60. doi request reprint Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study
    Olivia Fletcher
    Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Natl Cancer Inst 103:425-35. 2011
    ..Genome-wide association studies have identified several common genetic variants associated with breast cancer risk. It is likely, however, that a substantial proportion of such loci have not yet been discovered...
  61. doi request reprint Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast
    Felipe C Geyer
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Mod Pathol 23:951-60. 2010
    ....
  62. doi request reprint An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers
    Rachael Natrajan
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK
    Breast Cancer Res Treat 121:575-89. 2010
    ..g. proliferation, HER2 and ER signalling) may be driven by specific patterns of copy number aberrations...
  63. ncbi request reprint Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation
    Edurne Arriola
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Lab Invest 87:75-83. 2007
    ..For accurate results using Phi29 amplification, samples subjected to aCGH analysis should be combined with reference DNA amplified with the same method, using similar amounts of starting template...
  64. doi request reprint Changes in estradiol and testosterone levels in postmenopausal women after changes in body mass index
    Michael E Jones
    Division of Genetics and Epidemiology, The Institute of Cancer Research, University of London, Sutton SM2 5NG and London SW3 6JB, United Kingdom
    J Clin Endocrinol Metab 98:2967-74. 2013
    ..Endogenous sex hormones are risk factors for postmenopausal breast cancer. A potential route for favorable hormonal modification is weight loss...
  65. doi request reprint Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1
    Marieke Aarts
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research Breast Unit, UK
    Cancer Discov 2:524-39. 2012
    ..These features are characteristic of aggressive breast, and other, cancers for which WEE1 inhibitor combinations represent a promising targeted therapy...
  66. pmc High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing
    David Sims
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK
    Genome Biol 12:R104. 2011
    ..Our computational pipeline offers efficient screen analysis and the flexibility and scalability to quickly incorporate future developments in shRNA library technology...
  67. doi request reprint FGFR2 genotype and risk of radiation-associated breast cancer in Hodgkin lymphoma
    Yussanne P Ma
    Section of Cancer Genetics, Institute of Cancer Research, 15 Cotswold Rd, Sutton, Surrey, United Kingdom
    Blood 119:1029-31. 2012
    ..59, 95% confidence interval: 1.26-2.02; P = .000111). These data provide evidence that genetic variation in FGFR2 influences radiation-induced breast cancer risk...
  68. doi request reprint Genomic profiling of mitochondrion-rich breast carcinoma: chromosomal changes may be relevant for mitochondria accumulation and tumour biology
    Felipe C Geyer
    The Breakthrough Breast Cancer Research Centre, ICR, 237 Fulham Road, London SW3 6JB, UK
    Breast Cancer Res Treat 132:15-28. 2012
    ....
  69. pmc The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis
    Susan J Cleator
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, SW3 6JB, London, UK
    Breast Cancer Res 8:R32. 2006
    ..The aim of this study was to examine the effect of the cellular composition of biopsies on the error rates of multigene predictors of response of breast tumours to neoadjuvant adriamycin and cyclophosphamide (AC) chemotherapy...
  70. ncbi request reprint Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
    Hannah Farmer
    Cancer Research UK Gene Function and Regulation Group, London, UK
    Nature 434:917-21. 2005
    ..These results illustrate how different pathways cooperate to repair damage, and suggest that the targeted inhibition of particular DNA repair pathways may allow the design of specific and less toxic therapies for cancer...
  71. doi request reprint Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma
    Felipe C Geyer
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Histopathology 55:732-43. 2009
    ..The aim of this study was to determine whether MGA is clonal and whether it harbours chromosomal aberrations similar to those found in matched invasive ductal carcinoma of no special type (IDC-NST)...
  72. ncbi request reprint Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization
    Maryou B K Lambros
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Lab Invest 86:398-408. 2006
    ..In summary, this protocol enables the generation of probes mapping to any gene of interest that can be applied to FFPETS, allowing correlation of morphological features with gene copy number...
  73. ncbi request reprint Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition
    Nuala McCabe
    Cancer Research UK Gene Function and Regulation Group and The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Cancer Res 66:8109-15. 2006
    ....
  74. doi request reprint Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas
    David S P Tan
    Department of Gynaecologic Oncology, Royal Marsden Hospital NHS Foundation Trust, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Royal Marsden Hospital, London, United Kingdom
    Clin Cancer Res 17:1521-34. 2011
    ..Ovarian clear cell carcinomas (OCCC) are a drug-resistant and aggressive type of epithelial ovarian cancer. We analyzed the molecular genetic profiles of OCCCs to determine whether distinct genomic subgroups of OCCCs exist...
  75. doi request reprint Breast cancer molecular profiling with single sample predictors: a retrospective analysis
    Britta Weigelt
    Cancer Research UK, London Research Institute, London, UK
    Lancet Oncol 11:339-49. 2010
    ..Three microarray-based single sample predictors (SSPs) have been used to define molecular classification of individual samples. We aimed to establish agreement between these SSPs for identification of breast cancer molecular subtypes...
  76. pmc FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo
    Rachel Sharpe
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 17:5275-86. 2011
    ..Substantial evidence now links aberrant signaling by the fibroblast growth factor receptors (FGFR) to the development of multiple cancer types. Here, we examined the role of FGFR signaling in TN breast cancer...
  77. pmc Whole genome sequencing of matched primary and metastatic acral melanomas
    Samra Turajlic
    Signal Transduction Team, Division of Cancer Biology, Institute of Cancer Research, London SW3 6JB, United Kingdom
    Genome Res 22:196-207. 2012
    ..Furthermore, the majority of the SNVs in the primary tumor were propagated in the metastasis and one nonsynonymous coding SNV and one splice site mutation appeared to arise de novo in the metastatic lesion...
  78. pmc Genetic variants at chromosomes 2q35, 5p12, 6q25.1, 10q26.13, and 16q12.1 influence the risk of breast cancer in men
    Nick Orr
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
    PLoS Genet 7:e1002290. 2011
    ..Additional studies of well-defined patient subgroups could provide further insight into the biological basis of breast cancer development...
  79. pmc Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland
    Katherine E Sleeman
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, England, UK
    J Cell Biol 176:19-26. 2007
    ..These results are important for our understanding of cellular responses to hormonal stimulation in the normal breast and in breast cancer...
  80. pmc Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2
    Sarah A Martin
    Cancer Research UK Gene Function and Regulation Group, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    EMBO Mol Med 1:323-37. 2009
    ..While methotrexate has been used for many years as a cancer therapy, our observations suggest that this drug may have particular utility for the treatment of a subset of patients with tumours characterized by MSH2 mutations...
  81. ncbi request reprint Dynamic expression of Erbb pathway members during early mammary gland morphogenesis
    Olivia Wansbury
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Invest Dermatol 128:1009-21. 2008
    ..The expression patterns presented here suggest that multiple members of this signaling network are potential mediators of early mammary morphogenesis...
  82. ncbi request reprint Array CGH of fusion gene-positive leukemia-derived cell lines reveals cryptic regions of genomic gain and loss
    Sharon W Horsley
    Section of Haemato oncology, Institute of Cancer Research, London, United Kingdom
    Genes Chromosomes Cancer 45:554-64. 2006
    ..Finally, small regions of deletion and amplification, often including genes known to be involved in leukemia progression (for example MYC, TP53, CDKN2A, and KIT), were identified...
  83. doi request reprint PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors
    Konstantin J Dedes
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, SW3 6JB London, UK
    Sci Transl Med 2:53ra75. 2010
    ..Given that up to 80% of endometrioid endometrial cancers lack PTEN expression, our results suggest that PARP inhibitors may be therapeutically useful for a subset of endometrioid endometrial cancers...
  84. pmc Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls
    Olivia Fletcher
    Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London United Kingdom
    Cancer Epidemiol Biomarkers Prev 18:230-4. 2009
    ..Before such predictions are accepted by clinical geneticists, however, further population-based evidence is needed on the effect of CHEK2 1100delC and other moderate penetrance alleles in women with a family history of breast cancer...
  85. doi request reprint Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis
    Caterina Marchio
    The Breakthrough Breast Cancer Research Centre Institute of Cancer Research, London, UK
    J Pathol 219:16-24. 2009
    ..0 in FISH analysis is frequently related to gain or amplification of the centromeric region. Larger studies investigating the genetic profiles of CEP17 polysomic cases are warranted...
  86. doi request reprint Bringing DNA repair in tumors into focus
    Christopher J Lord
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    Clin Cancer Res 15:3241-3. 2009
    ..We discuss these results as well as the impact that double strand break repair biomarkers may have in cancer therapy...
  87. pmc Structural basis for recruitment of BRCA2 by PALB2
    Antony W Oliver
    Cancer Research UK DNA Repair Enzymes Group, Section of Structural Biology, 237 Fulham Road, London SW3 6JB, UK
    EMBO Rep 10:990-6. 2009
    ..The structure shows the molecular determinants of this important protein-protein interaction and explains the effects of both cancer-associated truncating mutants in PALB2 and missense mutations in the amino-terminal region of BRCA2...
  88. doi request reprint Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers
    Sarah A Martin
    Cancer Research UK Gene Function and Regulation Group, The Institute of Cancer Research, London, United Kingdom
    Cancer Res 71:1836-48. 2011
    ..Therefore, PINK1 represents a potential therapeutic target for the treatment of cancers characterized by MMR deficiency caused by a range of different gene deficiencies...
  89. ncbi request reprint BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency
    Nuala McCabe
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Cancer Biol Ther 4:934-6. 2005
    ..These results confirm that treatment with potent PARP inhibitors remains an exciting potential therapy for cancers involving BRCA1 or BRCA2 deficiency...
  90. ncbi request reprint The relationship between the roles of BRCA genes in DNA repair and cancer predisposition
    Andrew Tutt
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    Trends Mol Med 8:571-6. 2002
    ..An improved understanding of the interactions of BRCA1 and BRCA2 with other proteins in large macromolecular complexes is helping to reveal their exact role in DNA repair...
  91. pmc Functional and molecular characterisation of mammary side population cells
    Azra J Alvi
    Breakthrough Toby Robins Breast Cancer Centre, Institute of Cancer Research, London, UK
    Breast Cancer Res 5:R1-8. 2003
    ..Breast cancer is thought to arise in mammary epithelial stem cells. However, the identity of these stem cells is unknown...
  92. ncbi request reprint Phenotypic effects of heterozygosity for a BRCA2 mutation
    Madhuri Warren
    Cancer Research UK Gene Function and Regulation Group, The Breakthrough Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    Hum Mol Genet 12:2645-56. 2003
    ..Thus in certain cell types, genome instability might be driven directly by heterozygosity for BRCA2 mutation...
  93. pmc Receptor and secreted targets of Wnt-1/beta-catenin signalling in mouse mammary epithelial cells
    Paraic A Kenny
    Section of Gene Function and Regulation, Institute of Cancer Research, London, SW3 6JB, UK
    BMC Cancer 5:3. 2005
    ..Such alterations in the cellular transcriptional profile are believed to underlie the pathogenesis of these cancers. We have sought to identify novel target genes of this pathway in mouse mammary epithelial cells...
  94. doi request reprint IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma
    Peter Broderick
    Section of Cancer Genetics, Institute of Cancer Research, Royal Marsden Hospitals NHS Trust, London, UK
    Br J Haematol 148:413-5. 2010
    ..21 (95% confidence interval: 1.05-1.39, P = 0.009) and highlights the importance of inherited variation in B-cell developmental genes in the development of HL...
  95. ncbi request reprint Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance
    Susan Cleator
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
    Breast Cancer Res Treat 95:229-33. 2006
    ..We hypothesized that gene expression profiles predictive of AC response may be different from our previously published patterns with docetaxel...
  96. ncbi request reprint BRCA1 and BRCA2 as ovarian cancer susceptibility genes
    Heidi M Sowter
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    Carcinogenesis 26:1651-6. 2005
    ..Comparison of the pathogenesis of breast and ovarian cancers caused by BRCA mutation provides insight into the function of BRCA proteins as tumour suppressors in different cellular environments...
  97. doi request reprint The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module
    David Komander
    Section of Structural Biology, Institute of Cancer Research, Chester Beatty Laboratories, 237 Fulham Road, London SW3 6JB, UK
    Mol Cell 29:451-64. 2008
    ..Biochemical and functional characterization of the B box suggests a role as a protein-interaction module that contributes to determining the subcellular localization of CYLD...
  98. ncbi request reprint Targeting the DNA repair defect of BRCA tumours
    Nicholas Turner
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    Curr Opin Pharmacol 5:388-93. 2005
    ..This functional role in DNA repair could be exploited in the treatment of BRCA-deficient cancers by targeting the tumours with drugs that create DNA damage highly reliant on BRCA1 or BRCA2 for repair...
  99. doi request reprint DNA repair deficiency as a therapeutic target in cancer
    Sarah A Martin
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    Curr Opin Genet Dev 18:80-6. 2008
    ..It seems likely that other DNA repair processes can be targeted in a similar manner. These synthetic lethal approaches highlight how an understanding of DNA repair processes can be used in the development of novel cancer treatments...
  100. doi request reprint Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization
    Elizabeth Iorns
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW36JB, UK
    Biochem J 417:361-70. 2009
    ..Aside from identifying novel agents and targets for tamoxifen sensitization, this approach also provides evidence that performing chemical and genetic screens in parallel may be useful...
  101. ncbi request reprint Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk
    Olivia Fletcher
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK
    J Natl Cancer Inst 98:1014-8. 2006
    ..001). This heterogeneity could reflect either population-specific linkage disequilibrium with a functional variant or artifacts such as population stratification or publication bias...